Search

Displaying results 1231 - 1240 of 4004 in total
  1. Drug

    Avalglucosidase alfa

    go.drugbank.com/drugs/DB16099
    ApprovedInvestigational

    [L39205] The EMA approved the drug on June 24, 2022.[L42720] … [L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease.

  2. Drug

    Nicotinamide

    go.drugbank.com/drugs/DB02701
    ApprovedInvestigational

    An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent n...

    Mixtures: Botanic Heal boH Gauze Hydra So lution, Botanic Heal boH 360 Lifting So lutionProducts: Shieldlife Whitening Ion Mask
  3. Drug

    Carvedilol

    go.drugbank.com/drugs/DB01136
    ApprovedInvestigational

    [A182306] Carvedilol was granted FDA approval on 14 September 1995.[L7889]

  4. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    [A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953] … [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading

  5. Drug

    Phosmet

    go.drugbank.com/drugs/DB11448
    ExperimentalVet approved

    It is a non-specific insecticide. It is mainly used on apple trees to control codling moths. … It is also used on other fruit crops, ornamentals, and vines to control aphids, suckers, mites, and fruit flies.

  6. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    Atrasentan is a novel, selective endothelin A receptor antagonist (SERA). In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first...

  7. Drug

    Calaspargase pegol

    go.drugbank.com/drugs/DB14730
    ApprovedInvestigational

    Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890].

  8. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559] … Furthermore, it is the first non-immunosuppressive therapy for the reduction of proteinuria in IgAN.[L45315] The use of sparsentan may cause hepatotoxicity and embryo-fetal toxicity.

    Categories: Agents Acting on the Renin-Angiotensin System
  9. Drug

    Tick-borne encephalitis vaccine (whole virus, inactivated)

    go.drugbank.com/drugs/DB16611
    ApprovedInvestigational

    [L36120] TICOVAC was granted FDA approval on August 13, 2021.[L36050] … [A237520] Both vaccines are based on formaldehyde-inactivated whole virus.

  10. Drug

    Cinacalcet

    go.drugbank.com/drugs/DB01012
    ApprovedInvestigational

    Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.